Interactive Features

Test Your Knowledge

Quiz: Does Durvalumab Reduce Mortality in NSCLC With PD-L1 Expression?

04/11/2020

True or False: Durvalumab therapy yielded a numerically reduced risk for death compared with chemotherapy in patients with NSCLC and PD-L1 expression on ≥25% of tumor cells in a phase 3 trial.

True or False: Durvalumab...

04/11/2020

Oncology

Test Your Knowledge

Quiz: Does Adding Celecoxib to CRT Improve Survival in NSCLC?

04/02/2020

True or False: Adding celecoxib to concurrent CRT was not shown to improve survival in patients with NSCLC.

True or False: Adding celecoxib...

04/02/2020

Oncology

Test Your Knowledge

Quiz: Can Adding Pemetrexed to Bevacizumab Extend PFS in NSCLC?

03/11/2020

True or False: Adding pemetrexed to bevacizumab maintenance therapy prolonged PFS in patients with NSCLC.

True or False: Adding pemetrexed...

03/11/2020

Oncology

Test Your Knowledge

Quiz: TNMB Staging vs TNM Staging for DFS in NSCLC

03/05/2020

True or False: TNMB staging system may better approximate DFS in patients with NSCLC than conventional TNM staging.

True or False: TNMB staging...

03/05/2020

Oncology

Test Your Knowledge

Quiz: Is Efficacy of Nivolumab-Ipilimumab in Advanced NSCLC Based on PD-L1 Expression?

11/08/2019

True or False: The achievement of longer OS in patients with advanced NSCLC treated with first-line nivolumab plus ipilimumab versus chemo is heavily reliant on level of PD-L1 expression.

True or False: The achievement...

11/08/2019

Oncology

Test Your Knowledge

Quiz: Erlotinib With or Without Bevacizumab for Advanced EGFR-Positive NSCLC

10/29/2019

True or False: PFS rates with erlotinib therapy plus bevacizumab were superior to erlotinib alone for EGFR-positive NSCLC.

True or False: PFS rates with...

10/29/2019

Oncology

Test Your Knowledge

Quiz: Predicting Osimertinib Response in NSCLC

10/01/2019

True or False: Plasma and tissue genotyping for T790M mutations in patients with NSCLC can predict response to osimertinib.

True or False: Plasma and tissue...

10/01/2019

Oncology

Test Your Knowledge

Quiz: Bevacizumab, Pemetrexed Better as Single-Agents or Combo Therapy for NSCLC?

08/23/2019

True or False: Single-agent bevacizumab or pemetrexed is preferable to combo maintenance therapy with both drugs for advanced nonsquamous NSCLC.

True or False: Single-agent...

08/23/2019

Oncology

Test Your Knowledge

Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?

08/01/2019

True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.

True or false: Patients with...

08/01/2019

Oncology

Test Your Knowledge

Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?

08/01/2019

True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.

True or false: Patients with...

08/01/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology